Matches in SemOpenAlex for { <https://semopenalex.org/work/W4282967175> ?p ?o ?g. }
Showing items 1 to 71 of
71
with 100 items per page.
- W4282967175 endingPage "2681" @default.
- W4282967175 startingPage "2681" @default.
- W4282967175 abstract "Abstract RAS proteins are family of small GTP-binding proteins that play a major role in regulating cellular responses such as proliferation, differentiation, migration, and cell growth. RAS proteins function as molecular switches, cycling between inactive (GDP-bound) and active (GTP-bound) states, which relay cellular signals in response to extracellular stimuli. Aberrant RAS signaling plays a role in up to 30% of all human cancers, with the highest incidence occurring in carcinomas of the pancreas (63–90%), colon (36–50%), and lung (19–30%). Targeting the inactive, GDP bound KRASG12C has been a promising approach for generating novel anti RAS therapies, which is validated by the approval of AMG 510 (Lumakras) by the FDA. It is also known that KRASG12D also retains GTPase activity. Consequently, KRASG12D is one of the most important chemotherapeutic drug targets. KRASG12D is commonly observed in pancreatic cancer. Here we describe preclinical profile of a potent, selective, in-vivo tool compound, VRTX144. VRTX144 was potent in HPAC cell line, representing pancreatic adenocarcinoma, and a panel of KRASG12D mutated cell lines. It was found to be several folds less active in non-KRASG12D mutant cell lines. In vitro combination strategies with other targeted therapies such as EGFR, SHP2 and CDK4/6 inhibitor is also being investigated. VRTX144 exhibited low propensity for metabolism in microsomes, and has high protein bound. VRTX144 was found to have no adverse effect in hERG upto 10 uM. Citation Format: Prashant Kashinath Bhavar, Uday Kumar Surampudi, Partha Pratim Sarma, Mahesh Mohan Shidore, Anuj Ramesh Kshirsagar. Novel and selective inhibitors of KRASG12D [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 2681." @default.
- W4282967175 created "2022-06-17" @default.
- W4282967175 creator A5004253916 @default.
- W4282967175 creator A5014292175 @default.
- W4282967175 creator A5047706451 @default.
- W4282967175 creator A5055972219 @default.
- W4282967175 creator A5070765817 @default.
- W4282967175 date "2022-06-15" @default.
- W4282967175 modified "2023-10-16" @default.
- W4282967175 title "Abstract 2681: Novel and selective inhibitors of KRASG12D" @default.
- W4282967175 doi "https://doi.org/10.1158/1538-7445.am2022-2681" @default.
- W4282967175 hasPublicationYear "2022" @default.
- W4282967175 type Work @default.
- W4282967175 citedByCount "1" @default.
- W4282967175 countsByYear W42829671752023 @default.
- W4282967175 crossrefType "journal-article" @default.
- W4282967175 hasAuthorship W4282967175A5004253916 @default.
- W4282967175 hasAuthorship W4282967175A5014292175 @default.
- W4282967175 hasAuthorship W4282967175A5047706451 @default.
- W4282967175 hasAuthorship W4282967175A5055972219 @default.
- W4282967175 hasAuthorship W4282967175A5070765817 @default.
- W4282967175 hasConcept C121608353 @default.
- W4282967175 hasConcept C1491633281 @default.
- W4282967175 hasConcept C185592680 @default.
- W4282967175 hasConcept C207001950 @default.
- W4282967175 hasConcept C2780210213 @default.
- W4282967175 hasConcept C2781187634 @default.
- W4282967175 hasConcept C29537977 @default.
- W4282967175 hasConcept C502942594 @default.
- W4282967175 hasConcept C526805850 @default.
- W4282967175 hasConcept C54355233 @default.
- W4282967175 hasConcept C55493867 @default.
- W4282967175 hasConcept C62112901 @default.
- W4282967175 hasConcept C81885089 @default.
- W4282967175 hasConcept C86803240 @default.
- W4282967175 hasConcept C95444343 @default.
- W4282967175 hasConceptScore W4282967175C121608353 @default.
- W4282967175 hasConceptScore W4282967175C1491633281 @default.
- W4282967175 hasConceptScore W4282967175C185592680 @default.
- W4282967175 hasConceptScore W4282967175C207001950 @default.
- W4282967175 hasConceptScore W4282967175C2780210213 @default.
- W4282967175 hasConceptScore W4282967175C2781187634 @default.
- W4282967175 hasConceptScore W4282967175C29537977 @default.
- W4282967175 hasConceptScore W4282967175C502942594 @default.
- W4282967175 hasConceptScore W4282967175C526805850 @default.
- W4282967175 hasConceptScore W4282967175C54355233 @default.
- W4282967175 hasConceptScore W4282967175C55493867 @default.
- W4282967175 hasConceptScore W4282967175C62112901 @default.
- W4282967175 hasConceptScore W4282967175C81885089 @default.
- W4282967175 hasConceptScore W4282967175C86803240 @default.
- W4282967175 hasConceptScore W4282967175C95444343 @default.
- W4282967175 hasIssue "12_Supplement" @default.
- W4282967175 hasLocation W42829671751 @default.
- W4282967175 hasOpenAccess W4282967175 @default.
- W4282967175 hasPrimaryLocation W42829671751 @default.
- W4282967175 hasRelatedWork W1861078759 @default.
- W4282967175 hasRelatedWork W1972509069 @default.
- W4282967175 hasRelatedWork W2369550165 @default.
- W4282967175 hasRelatedWork W2379910594 @default.
- W4282967175 hasRelatedWork W2387704253 @default.
- W4282967175 hasRelatedWork W2561416304 @default.
- W4282967175 hasRelatedWork W3009790915 @default.
- W4282967175 hasRelatedWork W3022642502 @default.
- W4282967175 hasRelatedWork W3032526538 @default.
- W4282967175 hasRelatedWork W4382786356 @default.
- W4282967175 hasVolume "82" @default.
- W4282967175 isParatext "false" @default.
- W4282967175 isRetracted "false" @default.
- W4282967175 workType "article" @default.